Vertex to Acquire Crinetics for $10 Billion as Shares Surge 99%
CRNX•Vertex Pharmaceuticals will acquire Crinetics in a $10 billion all-cash transaction announced July 7. Crinetics shares surged 99% in intraday trading on the takeover news.
1. Deal Announcement
On July 7, Vertex Pharmaceuticals agreed to acquire Crinetics Therapeutics in a $10 billion all-cash transaction, valuing Crinetics at a substantial premium to its previous market capitalization.
2. Market Reaction
Following the announcement, Crinetics shares soared 99% in intraday trading, while Vertex shares climbed modestly, reflecting investor confidence in the strategic expansion of Vertex’s clinical pipeline.
